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0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: Evidence for the effectiveness of the new multidimensional GOLD
(Global Initiative for Chronic Obstructive Lung Disease) classification is currently limited.
The new classification has been validated in the United States and Europe, but validation in
Asian patients is still lacking. We examined the abilities of the GOLD 2013 classification to pre-
dict clinical outcomes in Taiwanese patients with chronic obstructive pulmonary disease
(COPD).
Methods: Patients with COPD were recruited from January 2006 to December 2012 and fol-
lowed up for exacerbation and mortality. The predictive abilities of various assessments were
compared through logistic regression analysis using receiver operating curve (ROC) estimations
and area under the curve (AUC).
Results: A total of 471 patients with COPD were analyzed. The GOLD 2013 groups at high risk of
exacerbation (C and D) experienced a higher average number of exacerbations per year
(2.1  3.1 vs. 0.3  1.0, p < 0.001) than the low risk groups (A and B). The mortality rates were
10.1% in GOLD 2013 Group A, 14.1% in Group B, 4.0% in Group C, and 30.5% in Group D. The AUC
values for GOLD 2013 and GOLD 2007 were 0.78 versus 0.67 (p < 0.001) for exacerbation, and
0.66 versus 0.61 (p Z 0.15) for mortality.have no conflicts of interest relevant to this article.
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Validation of GOLD classification 1259Conclusion: The GOLD 2013 classification has powerful ability to predict exacerbation, but
poor ability to predict mortality. The prognostic validity of the GOLD 2013 classification to pre-
dict exacerbations was better than the GOLD 2007 classification.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality throughout the world. The
World Health Organization has predicted that it will be the
third leading cause of death in the world by the year 2020.1
Importantly, more than one-half of patients with COPD in
the world are found in the Asia-Pacific region, where COPD is
estimated to occur in 10.6% of adults and where an estimated
1.5 million deaths attributable to COPD (cause of 12.4% of all
deaths in the Asia-Pacific region) occurred in 2004.2e5
The standards for the diagnosis and measurement of
disease severity in patients with COPD rely on the Global
Initiative for Chronic Obstruction Lung Disease (GOLD) 2007
criteria based on postbronchodilator spirometric values
only.1 However, COPD is a heterogeneous disease with
multiple clinical manifestations, and cannot be character-
ized using only the severity of airflow limitation.6 To better
classify the patients to predict the clinical course and to
guide treatment, the updated multidimensional GOLD 2011
and GOLD 2013 bases the classification of COPD on the
degree of dyspnea and history of exacerbations, in addition
to the forced expiratory volume in 1 second (FEV1).
7 The
difference between the GOLD 2011 and GOLD 2013 classi-
fication is that any hospital admission for COPD exacerba-
tions place a patient into the high risk of exacerbation
groups (Group C or D) using the 2013 classification, but two
or more exacerbations are needed to meet the criteria
using the GOLD 2011 classification.
Five studies have recently used data from existing co-
horts to validate the new classification system and to try to
determine whether the new classification predicts clinical
outcomes better than the 2007 classification. All of these
studies were validated in the United States or Europe.8e12
However, as far as we know, no such validation studies
have been conducted in Asia. We examined the abilities of
the GOLD 2013 classification to predict exacerbations and
mortality in patients with COPD in Taiwan, an Asian
country.
Patients and methods
Study population
We prospectively recruited 615 outpatients who had been
diagnosed with COPD at the National Cheng Kung University
Medical Center, Tainan, Taiwan between January 2006 and
December 2012. The patients included in the present study
were part of another previous study.13 All patients had
received regular management for COPD at our hospital for
> 1 year prior to their recruitment. COPD was defined ac-
cording to the diagnosis guidelines and criteria of GOLD1 asfollows: all patients were  40 years old, had typical
symptoms of COPD, and had a postbronchodilator FEV1/
forced vital capacity ratio < 70%. All pulmonary function
tests were performed according the standard protocols of
the American Thoracic Society.14 All patients were enrolled
in clinically stable condition. Patients with an illness other
than COPD that was likely to result in death within 2 years,
such as advanced malignancy or end-stage idiopathic pul-
monary fibrosis, were excluded from the study.
For included patients, age, body mass index (BMI), grade
on the modified Medical Research Council (mMRC) dyspnea
scale, the degree of comorbidity as evaluated using the
Charlson index, and lung function measurements with
postbronchodilator spirometric values were assessed at the
time of inclusion in the study. An acute exacerbation of
COPD was defined as an acute event characterized by a
worsening of the patient’s respiratory symptoms that is
beyond day-to-day variations which required medical
intervention including a short course of antibiotics and/or
oral steroids (moderate exacerbation) or hospitalization
(severe exacerbation). The number of exacerbations in the
preceding year and during follow up were recorded by
research assistants according to the patient’s chart as the
primary means of data collection; self-reported data was
used to supplement this data. The data collected for ex-
acerbations by chart review included the physician’s diag-
nosis of exacerbations requiring treatment with a short
course of antibiotics and/or oral steroids, or hospitaliza-
tion. To avoid omitting data for exacerbations in outside
hospitals, self-reported data for moderate or severe exac-
erbations was also recorded by research assistants at the
time of enrollment and during regular clinical visits, or by
telephone interview (if they missed the appointment).
Comorbidities evaluated using the Charlson index were
identified from the patient files and detailed interview. In
total, 471 patients with COPD were analyzed (Fig. 1). Both
inclusion and exclusion populations did not differ in de-
mographic characteristics selected variables and survival.
Detailed data for the comparison of inclusion and exclusion
groups were as follows: ratio of males: 93.4% vs. 97.9%,
p Z 0.17; age: 71.1  10.5 years versus 69.1  12.5 years,
p Z 0.76; BMI: 23.1  4.3 versus 22.5  3.8, p Z 0.36;
mMRC dyspnea scale: 1.9  1.0 versus 2.1  1.1, pZ 0.17;
FEV1 % of prediction: 61.6  22.5 versus 67.6  22.8,
p Z 0.08; ratio of patients that had frequent exacerbation
histories ( 2 moderate exacerbations/ 1 severe exacer-
bations): 42.0% versus 42.6%, p Z 0.76; Charlson index
score: 2.4  1.7 versus 2.1  1.6, pZ 0.26; ratio of current
smokers: 63.8% versus 57.1%, p Z 0.40; amount smoked:
51.4  40.8 pack-years versus 46.1  31.7 pack-years,
p Z 0.44; mortality rate: 19.3% versus 21.7%, p Z 0.69.
Patients were classified according to the GOLD 2007
classification1 based on the percent of the predicted
Figure 1 Flow diagram of the study cohort. COPDZ chronic obstructive pulmonary disease; FEV1Z forced expiratory volume in
1 second; FVCZ forced vital capacity; GOLDZ Global Initiative for Chronic Obstructive Lung Disease; mMRCZ modified Medical
Research Council.
1260 C.-Z. Chen et al.postbronchodilator FEV1 as follows; mild stage (FEV1  80),
moderate stage (50  FEV1 < 80), severe stage
(30  FEV1 < 50), and very severe stage (FEV1 < 30). The
present study used the GOLD 2011 and 2013 classification7
to divide patients into four groups (Groups AeD) based on
the percent of predicted postbronchodilator FEV1, self-
reported severity of dyspnea (mMRC), and risk of recur-
rent exacerbations according to GOLD guidelines. Group A
comprised patients with a low risk of exacerbations and less
symptoms of dyspnea (mMRC 0e1). Group B comprised
patients with a low risk of exacerbations and more symp-
toms of dyspnea (mMRC  2). Group C comprised patients
with a high risk of exacerbations and less symptoms of
dyspnea (mMRC 0e1). Group D comprised patients with a
high risk of exacerbations and more symptoms of dyspnea.
A high risk of exacerbations was defined by 2011 GOLD as an
FEV1 < 50% of predicted exacerbations and/or two or more
moderate and severe exacerbations in the preceding year,
and by the 2013 GOLD as an FEV1 < 50% of predicted
exacerbation and/or two or more moderate exacerbations
or one or more severe exacerbation in the preceding year.
Patients in Subgroups C1 and D1 met spirometry criteria
only, patients in Subgroups C2 and D2 met exacerbation
criteria only, and patients in Subgroups C3 and D3 met both
spirometry and exacerbation criteria.Outcomes
The prospective exacerbation rates were calculated for 338
patients with COPD who were followed up > 1 year after
enrollment. The survival status of 471 patients was evalu-
ated using prospective observations as described in our
previous study.13 The study was approved by the Research
Review Board of the National Cheng Kung University Hospital
and all participants provided written informed consent.Statistical analysis
Continuous variables are presented as the mean and stan-
dard deviation. Nominal variables were compared using the
c2 test. Comparisons between groups were performed using
analysis of variance. To determine independent variables of
mortality, we used multivariate analysis to evaluate the
association of variables such as age, BMI, and mMRC dys-
pnea grade.
The abilities of GOLD 2007 and 2013 to predict exacer-
bations, all-cause mortality, and respiratory mortality were
compared through logistic regression analysis with receiver
operating curve (ROC) estimations and intramodel area
under the curve (AUC) comparisons. A p value < 0.05 was
Figure 2 Distribution of patients in the GOLD 2007, 2011,
and 2013 classifications. GOLD Z Global Initiative for Chronic
Obstructive Lung Disease.
Validation of GOLD classification 1261considered statistically significant. Analyses were per-
formed using the SAS 9.2 statistical software (SAS Institute
Inc., Cary, NC, USA).
Results
A total of 471 participants were analyzed, 420 patients with
COPD (420/471; 89.2%) had a smoking history and the other
51 patients were nonsmokers; changes in the distribution of
patients from the GOLD 2007 to the GOLD 2011 and 2013
classifications are shown in Fig. 2. There were more pa-
tients in the most severe group (Group D) in the GOLD 2011
and 2013 classifications than in the GOLD 2007 classification
and there were a relatively small number of patients in
Group C in the new GOLD classification. The characteristicsTable 1 Characteristics of 471 patients according to the GOLD
GOLD 2013 Group A (n Z 119) Group B (n Z
Male (%) 93 91
Age (y) 67.8 (11.8) 75.8 (9.2)
BMI (kg/m2) 23.8 (3.7) 23.9 (3.9)
mMRC score 0.8 (0.5) 2.2 (0.5)
FEV1% pred 79.0 (16.0) 72.4 (17.2)
Exacerbations (%)a 0 0
Charlson index 2.2 (1.6) 2.4 (1.7)
Current smoker (%) 56.8 66.3
Smoking (pack-years) 48.5 (38.6) 51.1 (41.3)
CV diseases (%)
Inhaled therapy (%)
25.2 29.4
LABA þ ICS 23.5 27.8
LAMA 32.8 41.1
Triple therapyb 3.4 5.9
Data are presented as the mean (standard deviation), unless otherwi
BMI Z body mass index; CV disease Z cardiovascular disease (inc
congestive heart failure); FEV1 % pred Z forced expiratory volume
Obstructive Lung Disease; LABA Z long acting beta2 agonists; LA
LAMA Z long-acting muscarine antagonist; mMRC Z modified Medica
a Patient had two or more exacerbations requiring medical interv
requiring hospitalization in previous years.
b Triple therapy Z combined inhaled steroids, long acting beta2 agof the patients defined by GOLD 2013 are shown in Table 1.
Patients with more severe dyspnea (Groups B and D) were
older (73.2  0.6 years vs. 67.4  0.8 years, p < 0.001), and
had a higher prevalence of cardiovascular diseases (32.5%
vs. 23.7%, p Z 0.043) than patients with less severe dys-
pnea (Groups A and C).
The median follow-up duration in this study was of 2.9
(1.4e4.1) years during which time 91 patients had died; the
mortality rate was 19.3%. The cause of death was
respiratory-specific in 57.1%, cardiovascular-specific in
19.8%, cancer-specific in 16.5%, and relative to other cause
in 6.6% of patients. The GOLD 2013 classification had a good
ability to predict exacerbations (Table 2). Patients in the
high risk groups (Groups C and D) experienced a higher
average number of total exacerbations (2.1  3.1 vs.
0.3 1.0, p< 0.001) and severe exacerbations (0.7 1.5 vs.
0.1 0.5, p< .001) during follow up the 1st year than those in
the low risk groups (Groups A and B). Logistic regression
analysis showed that each quartile increase in theGOLD 2013
grading was associated with increased odds of exacerbations
(Table 3). Patients in Group C had a higher risk of exacer-
bations than those in Group B with an odds ratio (OR) of 7.3
(95% confidence interval, 3.2e17.9) for total exacerbations
and an OR of 4.9 (95% confidence interval, 2.0e12.4) for
severe exacerbations. ROC analysis showed a significantly
higher predictive ability for the GOLD 2013 than the GOLD
2007 classification, for total exacerbations (0.78 vs. 0.67,
p < 0.001) and severe exacerbations (0.78 vs. 0.66,
p < 0.001) during the 1st year of observation (Table 3).
KaplaneMeier analysis of all-cause mortality showed
that each quartile increase in the GOLD 2007 staging was
associated with increased mortality. For the GOLD 2013
grading, the mortality in Group B was higher than in Group
C (p Z 0.044; Fig. 3). The all-cause and respiratory2013 classification.
92) Group C (n Z 50) Group D (n Z 210) p
94 94 0.823
66.4 (10.6) 72.0 (9.3) <0.001
23.1 (5.2) 22.4 (4.4) 0.005
0.8 (0.4) 2.6 (0.7) <0.001
58.6 (20.1) 47.8 (18.9) <0.001
72.0 77.1 <0.001
2.3 (1.7) 2.6 (1.7) 0.144
55.1 68.8 0.089
46.3 (45.5) 54.5 (40.7) 0.481
20.0 33.8 0.155
34.0 42.4 0.003
46.0 36.2 0.347
10.6 10.8 0.069
se stated.
luding old myocardial infarction, coronary artery disease, and
in 1 second % predicted; GOLD Z Global Initiative for Chronic
BA þ ICS Z long acting beta2 agonists and inhaled steroid;
l Research Council.
ention with steroid or antibiotics or one or more exacerbations
onists, and long-acting muscarine antagonist.
Table 2 Prognosis for patients according to the GOLD 2013 classification.a,b
GOLD 2013 Group A Group B Group C Group D p
Average no. of exacerbations/y
Total exacerbationsa 0.21 (0.64) 0.44 (1.27) 1.54 (2.23) 2.24 (3.33) <0.001
Severe exacerbations 0.07 (0.38) 0.17 (0.61) 0.24 (0.58) 0.87 (1.69) <0.001
Mortality, n (%)
All-cause 12 (10.1) 13 (14.1) 2 (4.0) 64 (30.5) <0.001
Respiratory 2 (1.7) 8 (8.7) 1 (2.0) 41 (19.5) <0.001
Cardiovascular 5 (4.2) 3 (3.3) 1 (2.0) 9 (4.3) 0.800
Cancer 3 (2.5) 1 (1.1) 0 (0) 11 (5.2) 0.335
Data are presented as the mean (standard deviation), unless otherwise stated.
GOLD Z Global Initiative for Chronic Obstructive Lung Disease.
a In total, 471 patients were analyzed for mortality and 338 patients were analyzed for exacerbation and hospitalization, both analyses
were adjusted for age.
b Total exacerbations are exacerbations including moderate (exacerbations requiring medical intervention with steroid or antibiotics)
and severe exacerbations (exacerbations requiring hospitalization).
1262 C.-Z. Chen et al.mortality rates for GOLD 2013 classifications are presented
in Table 2. The AUC estimates for the GOLD 2013 and 2007
classifications were 0.66 versus 0.61 (p Z 0.15) for all-
cause mortality and 0.71 versus 0.65 (p Z 0.19) for respi-
ratory mortality (Table 3). There were no significant dif-
ferences for the GOLD 2013 and GOLD 2007 classifications in
predicting mortality.
A multivariate analysis for the predictors of mortality
showed that age (p Z 0.012), lower BMI (p Z 0.002), an
mMRC score  2 (p Z 0.013), the Charlson index score
(p < 0.001), and being a current smoker (p Z 0.040) were
significant independent predictors of mortality, however,
exacerbation risk by history (p Z 0.055) and a FEV1 < 50%
of prediction (p Z 0.429) was not.
In Group C, 28.0% of patients were in Group C1, 50.0% in
Group C2, and 22.0% in Group C3. The distribution and
characteristics of the groups C1eC3 and D1eD3 are shown
in Tables 4 and 5. Patients in the D1eD3 groups have
significantly different prospective exacerbation rates
(Table 6).Table 3 Exacerbations and mortality using the GOLD 2013 and G
receiver operating curve estimations.a,b
GOLD classification Total exacerbations Severe exace
2013
Group A 1 1
Group B 1.9 (0.8e4.5) 2.5 (0.8e7.6)
Group C 13.9 (5.5e35.0) 12.1 (4.0e36.
Group D 17.3 (8.2e36.8) 22.6 (8.6e59.
AUC 0.78 (0.73e0.83) 0.78 (0.73e0.
2007
Stage 1 1 1
Stage 2 2.7 (1.5e4.9) 2.3 (1.2e4.3)
Stage 3 4.3 (2.3e8.4) 3.8 (1.9e7.5)
Stage 4 15.4 (4.7e50.3) 12.9 (4.4e37.
AUC 0.67 (0.61e0.73) 0.66 (0.60e0.
Data are presented as odds ratio (95% confidence interval) and AUC.
AUC Z area under the curve; GOLD Z Global Initiative for Chronic O
a In total, 471 patients were analyzed for mortality and 338 patient
b Total exacerbations are exacerbations including moderate (exacer
and severe exacerbations (exacerbations requiring hospitalization).Discussion
We validated the updated GOLD 2013 classification in
Taiwanese patients with COPD. As far as we know, this is the
first validation study for the new GOLD classification per-
formed in an Asian population. Most of our findings were in
accordance with recent results from the United States and
Europe, which are briefly summarized in Table 7.8e12 Our
findings on the distribution of patients, characteristics of
patients, and ability to predict outcomes were very similar
to the results from the Copenhagen9 and GenKOLS12 studies.
Common findings in these two studies and in the present
study were as follows: (1) the distribution of patients was
similar to a relatively lower number of Grade C patients; (2)
patients with more severe dyspnea (Groups B and D) were
older and had more cardiovascular disease than patients in
the other groups; (3) mortality was highest in Group D, and
Group C tended to have lower mortality than Group B; and
(4) the predictive ability of the new GOLD classification and
GOLD 2007 did not differ significantly in mortality. However,OLD 2007 classifications and logistic regression analyses with
rbations All-cause mortality Respiratory mortality
1 1
1.4 (0.6e3.3) 5.5 (1.1e26.5)
0) 0.4 (0.1e1.8) 1.2 (0.1e13.9)
2) 4.0 (2.1e7.8) 14.5 (3.4e61.1)
83) 0.66 (0.60e0.72) 0.71 (0.64e0.77)
1 1
2.0 (1.0e4.0) 2.0 (0.8e5.3)
2.5 (1.2e5.1) 3.4 (1.3e8.8)
9) 5.0 (2.0e12.2) 7.8 (2.6e23.4)
72) 0.61 (0.55e0.68) 0.65 (0.57e0.73)
bstructive Lung Disease.
s were analyzed for exacerbation and hospitalization.
bations requiring medical intervention with steroid or antibiotics)
AB
p
p
Figure 3 KaplaneMeier survival curves according to (A) the GOLD 2007 classification and (B) the GOLD 2013 classification.
GOLD Z Global Initiative for Chronic Obstructive Lung Disease.
Validation of GOLD classification 1263several important differences between the two studies and
the present study were noted. In the GenKOLS12 study: (1)
the risk of exacerbation was only based on COPD hospitali-
zation, and was not defined according to the GOLD 2011
guideline; (2) only the long-term prognosis (8 years) was
analyzed; and (3) the cohort did not include patients with
mild severity (GOLD Stage 1). In the Copenhagen study,9
prebronchodilator values were used to diagnose and clas-
sify patients and postbronchodilator values were not used asthe guideline recommended. By contrast, the severity of
COPD of our patients was distributed from mild (GOLD Stage
1) to very severe (GOLD Stage 4). We also used post-
bronchodilator values to diagnose and classify patients with
COPD and to stratify the high risk groups (Groups C and D)
according to the 2013 classification. Therefore, the present
study improved on the limitations of the Copenhagen9 and
GenKOLS12 studies and represents a significant extension of
the current knowledge.
Table 4 Characteristics of 50 patients within Group C according to the GOLD 2013 classification.
GOLD 2013 Group Group C1 (n Z 14) Group C2 (n Z 25) Group C3 (n Z 11) p
Male (%) 93 92 100 0.460
Age (y) 65.7 (10.6) 67.9 (11.4) 63.9 (9.1) 0.564
BMI (kg/m2) 22.5 (6.0) 23.8 (3.3) 22.1 (7.5) 0.617
mMRC score 0.9 (0.3) 0.7 (0.5) 0.9 (0.3) 0.191
FEV1 % pred 41.6 (9.5) 74.4 (15.4) 44.5 (6.3) <0.001
Charlson index 1.6 (1.2) 2.4 (1.74) 2.8 (2.6) 0.197
Current smokers (%) 50.0 54.2 63.6 0.785
Smoking (pack-years) 33.1 (24.3) 55.0 (58.8) 43.8 (28.0) 0.382
CV diseases (%) 7.1 24.0 27.3 0.303
Inhaled therapy (%)
LABA þ ICS 29 36 36 0.878
LAMA 64 40 36 0.263
Triple therapya 7.7 13.0 9.1 0.865
Data are presented as the mean (standard deviation), unless otherwise stated.
BMI Z body mass index; CV disease Z cardiovascular disease (including old myocardial infarction, coronary artery disease, and
congestive heart failure); FEV1 % pred Z forced expiratory volume in 1 second % predicted; GOLD Z Global Initiative for Chronic
Obstructive Lung Disease; LABA Z long acting beta2 agonists; LABA þ ICS Z long acting beta2 agonists and inhaled steroid;
LAMA Z long-acting muscarine antagonist; mMRC Z modified Medical Research Council.
a Triple therapy Z combined inhaled steroids, long acting beta2 agonists, and long-acting muscarine antagonist.
1264 C.-Z. Chen et al.In the Copenhagen9 and COPDGene11 studies, patients in
Group B had a higher risk of exacerbation than those in
Group C. By contrast, we found that patients in Group C had
a higher risk of exacerbations than those in Group B with an
OR of 7.3 for total exacerbations and an OR of 4.9 for severe
exacerbations. In the Copenhagen9 and COPDGene11
studies, the majority of patients were classified into
Group C on the basis of a low FEV1 (78% and 75%, respec-
tively). By contrast, in the present study, most patients
were classified into Group C, because of a history of pre-
vious exacerbations (50%). Exacerbation frequency is aTable 5 Characteristics of 210 patients within Group D accordi
GOLD 2013 Group Group D1 (n Z 48) Grou
Male (%) 94 95
Age (y) 69.1 (6.9) 74.4
BMI (kg/m2) 21.8 (5.1) 23.5
mMRC score 2.6 (0.7) 2.4 (
FEV1 % pred 37.3 (9.7) 67.4
Charlson index 2.0 (1.3) 2.7 (
Current smokers (%) 63.0 67.6
Smoking (pack-years)
CV diseases (%) 59.5 (38.3) 51.6
Inhaled therapy (%) 20.8 36.5
LABA þ ICS 50 36.5
LAMA 35.4 35.1
Triple therapya 8.7 5.6
Data are presented as the mean (standard deviation), unless otherwi
BMI Z body mass index; CV disease Z cardiovascular disease (inc
congestive heart failure); FEV1 % pred Z forced expiratory volume
Obstructive Lung Disease; LABA Z long acting beta2 agonists; LA
LAMA Z long-acting muscarine antagonist; mMRC Z modified Medica
a Triple therapy Z combined inhaled steroids, long acting beta2 agstrong predictor of recurrent exacerbations, however, FEV1
is a weak predictor.15 The different ratio of patients in
Group C is a possible explanation for the discrepancy be-
tween recent studies and ours results.
Survival was better in Group C than in Group B. Johan-
nessen et al12 suggested the greater prevalence of cardio-
vascular disease in Group B as a possible explanation for
their poor survival. In the present study, patients in Group B
had more cardiovascular diseases and more symptoms of
dyspnea, and more patients were current smokers and they
were older than those in Group C. Multivariate analysisng to the GOLD 2013 classification.
p D2 (n Z 74) Group D3 (n Z 88) p
94 0.981
(9.6) 71.7 (9.6) 0.007
(3.9) 21.8 (4.2) 0.025
0.6) 2.9 (0.7) <0.001
(14.7) 37.1 (11.1) <0.001
1.7) 2.8 (1.8) 0.028
72.7 0.501
(42.8) 54.5 (40.3) 0.610
38.6 0.079
43.2 0.330
37.5 0.945
16.3 0.081
se stated.
luding old myocardial infarction, coronary artery disease, and
in 1 second % predicted; GOLD Z Global Initiative for Chronic
BA þ ICS Z long acting beta2 agonists and inhaled steroid;
l Research Council.
onists, and long-acting muscarine antagonist.
Table 6 Prognosis for patients within Group D according to the GOLD 2013 classification.a
GOLD 2013 Group Group D1 Group D2 Group D3 p
Average number of exacerbations/y
Total exacerbationsb 0.75 (1.35) 2.17 (3.32) 3.00 (3.75) 0.012
Severe exacerbations 0.31 (0.54) 0.76 (1.48) 1.25 (2.10) 0.038
Mortality, n (%)
All-cause 10 (20.8) 22 (29.7) 32 (36.4) 0.159
Respiratory 7 (14.6) 13 (17.6) 21 (23.9) 0.370
Cardiovascular 0 (0.0) 6 (8.1) 3 (3.4) 0.039
Cancer 3 (6.3) 3 (4.1) 5 (5.7) 0.838
Data are presented as the mean (standard deviation), unless otherwise stated.
GOLD Z Global Initiative for Chronic Obstructive Lung Disease.
a In total, 210 patients were analyzed for mortality and 143 patients were analyzed for exacerbation and hospitalization.
b Total exacerbations Z exacerbations including moderate (exacerbations requiring medical intervention with steroid or antibiotics)
and severe exacerbations (exacerbations requiring hospitalization).
Table 7 Validation studies for the new multidimensional GOLD classification.
Han et al.11
COPDGene
Lange et al.9
Copenhagen
Soriano et al.10
COCOMICS
Johannessen et al.12
GenKOLS
Leivseth et al.8
HUNT
Present study
Patient
source
Academic
centers/USA
General
population/
Denmark
Tertiary
centers/Spain
Hospital þ general
population/Norway
General
population/
Norway
Academic
center/Taiwan
Patient no. 4484 6628 3363 662/250 1540 471
Outcomes
of survey
Exacerbation Exacerbation,
hospitalization,
and mortality
All-cause
mortality
Hospitalization
and mortality
All-cause
mortality
Exacerbation,
and mortality
Follow-up
duration (y)
1.7 (mean) 4.3 (mean) 10 (at least) 7.6 (median) 14.6 (median) 2.9 (median)
Distribution (%)
A 33.6 77.4 33.6 21.2 60.7 25.5
B 20.5 14.1 16.3 29.3 17.9 20.0
C 7.9 4.1 17.7 6.3 11.8 10.4
D 38.0 4.4 32.3 43.3 9.6 44.2
Major
findings
(1) Relatively
lower number
of group C
patients
(1) GOLD 2011
predicted
exacerbation
better than
GOLD 2007
(1) GOLD 2011
predicted
mortality is no
different than
GOLD 2007
(1) GOLD 2011
predicted
hospitalization
and mortality is
no different
than GOLD 2007
(1) GOLD 2007
predicted
mortality
better than
GOLD 2011
(1) GOLD 2013
predicted
exacerbation better
than GOLD 2007
(2) Significant
heterogeneity
in prospective
exacerbation
rates in the
Group D
subcategories
(2) Relatively
lower number
of Group C
patients
(2) Relatively
lower number
of Group C patients
(2) Relatively lower
number of Group C
patients
(3) Survival is
better in
C than B,
most likely
caused by heart
disease or
cancer
(3) Survival is
better in Group C
than B
(3) Significant
heterogeneity in
prospective
exacerbation rates
in the Group D
subcategories
(4) Survival is better
in Group C than B
GOLD Z Global Initiative for Chronic Obstructive Lung Disease.
Validation of GOLD classification 1265
1266 C.-Z. Chen et al.showed that age, dyspnea (mMRC scale  2), and being a
current smoker were significant independent predictors of
mortality. Our findings support the importance of dyspnea
as a predictor of mortality. Moreover, age and smoking
status were also possible explanations other than cardio-
vascular diseases for poorer survival in Group B than in
Group C.
The prognosis for exacerbations in the Subgroups D1eD3
showed considerable heterogeneity. Patients in Subgroup
D3 had the highest prospective total exacerbation rate and
severe exacerbation rate, followed by Subgroups D2 and
D1. These findings were in accordance with the Copenha-
gen9 and COPDGene11 studies. which show that the criteria
for category assignment significantly alters future exacer-
bation risk.
One limitation of the present study was that few women
(6.6%) were enrolled. The majority of patients with
smoking-related COPD in Taiwan are men (smoking preva-
lence for women is < 5 %).4 In contrast to industrialized
countries in the West, COPD morbidity remains male-
predominant in Asian countries.2e4 In addition, the
limited number of patients in the Group C and Group D
subgroups, especially in the Group C subgroups, limited the
ability to find statistically significant associations.
In conclusion, the validity of GOLD 2013 to predict total
and severe exacerbations was better than GOLD 2007 but did
not differ significantly inmortality. GOLDGroupsC andDwere
heterogeneous; the prognosis for the Group D subgroups
(D1eD3) showed significant heterogeneity regarding the
ability to predict exacerbations. Group D should be further
subdivided when planning management in clinical practice.
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